Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
20 12월 2023 - 10:30PM
Business Wire
- Secretary Ross has over 55 years’ experience as a business
leader, banker, and investor and is the former Chairman and Chief
Strategy Officer of WL Ross & Co.
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
biologics and cell therapies intended to enhance the function of
Regulatory T Cells (Tregs), today announced that it has appointed
Secretary Wilbur Ross to its board of directors, effective
immediately. Coya intends to leverage Secretary Ross’s extensive
experience in both the business and investment community to help
guide strategic partnering activities, capital markets initiatives
and drug development programs.
Secretary Ross explained, “I am excited to join the Board of
Coya. I believe the Company is uniquely positioned in translating
the science of regulatory T cell biology and inflammation into
promising therapies for terrible diseases such as Amyotrophic
Lateral Sclerosis, Alzheimer's Disease and other conditions with
high unmet need. I am pleased to provide my support and advocacy to
help drive Coya’s important mission.”
Wilbur L. Ross, Jr. was sworn in by Vice President Mike Pence as
the 39th U.S. Secretary of Commerce on February 28, 2017. Secretary
Ross is the former Chairman and Chief Strategy Officer of WL Ross
& Co. LLC and has over 55 years of investment banking and
private equity experience. Secretary Ross has been chairman or lead
director of more than 100 companies operating in more than 20
different countries. Named by Bloomberg Markets as one of the 50
most influential people in global finance, Secretary Ross is the
only person elected to both the Private Equity Hall of Fame and the
Turnaround Management Hall of Fame.
“I am delighted that Secretary Ross will bring his long and
noteworthy experience in capital markets and business operations to
Coya. By partnering with Dr. Reddy’s and by closing our recent
financing transaction, we believe we have executed a major
transformation of our company. We’re entering a new phase of our
development and we believe Secretary Ross will be integral in
helping drive us towards our ambitious goals,” stated Howard
Berman, Ph.D., CEO of Coya.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to a sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system. Coya’s investigational
product candidate pipeline leverages multiple therapeutic
modalities aimed at restoring the anti-inflammatory and
immunomodulatory functions of Tregs. Coya’s lead therapeutic
programs includes Treg-enhancing biologics (COYA 300 Series product
candidates) COYA 301 and COYA 302, which are intended to enhance
Treg function and expand Treg numbers. COYA 301 is a cytokine
biologic for subcutaneous administration intended to enhance Treg
function and expand Treg numbers in vivo, and COYA 302 is a
biologic combination for subcutaneous and/or intravenous
administration intended to enhance Treg function while depleting T
effector function and activated macrophages. These two mechanisms
may be additive or synergistic in suppressing inflammation. For
more information about Coya, please visit
www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to known and
unknown risks, uncertainties, assumptions and other factors
including, but not limited to, those related to risks associated
with the impact of COVID-19; the success, cost and timing of our
product candidate development activities and ongoing and planned
clinical trials; our plans to develop and commercialize targeted
therapeutics; the progress of patient enrollment and dosing in our
preclinical or clinical trials; the ability of our product
candidates to achieve applicable endpoints in the clinical trials;
the safety profile of our product candidates; the potential for
data from our clinical trials to support a marketing application,
as well as the timing of these events; our ability to obtain
funding for our operations; development and commercialization of
our product candidates; the timing of and our ability to obtain and
maintain regulatory approvals; the rate and degree of market
acceptance and clinical utility of our product candidates; the size
and growth potential of the markets for our product candidates, and
our ability to serve those markets; our commercialization,
marketing and manufacturing capabilities and strategy; future
agreements with third parties in connection with the
commercialization of our product candidates; our expectations
regarding our ability to obtain and maintain intellectual property
protection; our dependence on third party manufacturers; the
success of competing therapies or products that are or may become
available; our ability to attract and retain key scientific or
management personnel; our ability to identify additional product
candidates with significant commercial potential consistent with
our commercial objectives; ; and our estimates regarding expenses,
future revenue, capital requirements and needs for additional
financing. We have based these forward-looking statements largely
on our current expectations and projections about future events and
trends that we believe may affect our financial condition, results
of operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231220291772/en/
David Snyder, CFO, Coya Therapeutics, Inc
david@coyatherapeutics.com
Hayden IR James Carbonara (646)-755-7412 james@haydenir.com
Media Contact Jessica Starman media@coyatherapeutics.com
Coya Therapeutics (NASDAQ:COYA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Coya Therapeutics (NASDAQ:COYA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024